Infants are not small children - four maturing organ systems, three conditioning drugs, and a protocol that treats the first year of life as one category
also called developmental pharmacology · ontogeny of drug metabolism · organ immaturity infants · paediatric pharmacokinetics · infants are not small adults
A baby's liver enzymes, kidneys, gut and body water are all still changing month by month during the first year, so the same dose of the same drug does something different at two months and at eleven months. The transplant protocol for these babies treats the whole first year as one group.
The same thing, for a scientist
Developmental pharmacology is the standing statement that drug disposition in infants and children is governed by processes that change with age rather than simply scaling with size [E1]. Four of those processes bear directly on transplant conditioning: glomerular filtration, which is still maturing towards adult values through the first one to two years and governs fludarabine's active circulating species; cytochrome P450 ontogeny, where CYP2B6 and CYP3A4 activate thiotepa to TEPA and cyclophosphamide to its phosphoramide mustard on developmentally staged schedules; glutathione conjugation, which clears busulfan; and body composition, since total body water per kilogram is highest in infancy and alters the volume of distribution of every hydrophilic agent. The consequence is measurable rather than theoretical: in a physiologically based model of paediatric fludarabine, predicting individual exposure worked better from NUCLEAR glomerular filtration rate than from estimated GFR [E2]; and at the same busulfan exposure, children under 3 years had mixed donor myeloid chimerism in 45.2% against 1.9% of older children [E3]. Interfant-06's conditioning chapter contains no age-based dose adjustment at all, while the same protocol's frontline chapters do [E4].
The four systems, and which conditioning drug each one governs1 deeper
| maturing system | what changes in year one | conditioning agent affected |
|---|---|---|
| glomerular filtration | GFR rises steeply from birth towards adult values over 1-2 years | fludarabine - F-ara-A is renally cleared |
| cytochrome P450 ontogeny | CYP2B6 and CYP3A4 expression are low at birth and rise on developmentally staged schedules | thiotepa (desulfuration to TEPA) and cyclophosphamide (4-hydroxylation) |
| glutathione conjugation | GST activity and hepatic glutathione content change with age | busulfan - cleared by GSTA1 conjugation |
| body composition | total body water per kilogram is highest in infancy and falls through childhood | every hydrophilic agent's volume of distribution |
Three of the four Interfant-06 conditioning agents, plus both modern additions, sit in that table. The one that does not is melphalan, whose alkylation is chemical and whose clearance is partly renal - so it lands in the first row anyway.
The standing reference for this is Kearns and colleagues' review of developmental pharmacology, whose whole subject is that drug disposition, action and therapy differ in infants and children for reasons of ontogeny rather than size 1.
The measurement that makes it concrete: estimated GFR fails where it matters
A physiologically based pharmacokinetic model of fludarabine in 28 paediatric transplant patients predicted individual exposure better when informed by nuclear GFR (a directly measured clearance study) than by estimated GFR 2.
That matters most in infants for a specific reason. Estimated GFR in children is computed from serum creatinine, and creatinine is generated by skeletal muscle. An infant has very little muscle, so serum creatinine is low regardless of renal function and eGFR formulae are at their least informative in the age group whose renal function is changing fastest.
So the covariate that governs the dose of the drug that prevents graft rejection is estimated worst in the patient in whom graft rejection is most catastrophic.
The same exposure does not do the same thing
The strongest available demonstration that age matters independently of pharmacokinetics: in 105 children conditioned with myeloablative busulfan for non-malignant disease, the 3-year cumulative incidence of mixed donor myeloid chimerism was 45.2% below 3 years of age against 1.9% at or above 3 years, and 'there was no difference in busulfan exposure between the groups' 3.
Read the second clause. This is not a dosing failure. These children achieved the same drug exposure and the drug did less. The authors' proposed explanation is greater marrow reserve in younger children, which is a pharmacodynamic age effect rather than a pharmacokinetic one - and it means that perfecting exposure-guided dosing would not have closed this gap.
The finding is in non-malignant disease, where mixed chimerism means partial correction rather than residual leukaemia, and it has not been tested in infant ALL. But it is the clearest published statement that the first years of life differ from later childhood in a way that dosing cannot fix.
The protocol adjusts chemotherapy for age and does not adjust conditioning
Interfant-06 reduces frontline chemotherapy doses by age - this graph's drug-cyclophosphamide entry records the rule as two-thirds under 6 months and three-quarters from 6 through 12 months. The conditioning chapter has no equivalent 4. Its only size rule is for obesity, and its dosing is a fixed mg/kg or mg/m2 for every infant from birth to twelve months.
Two readings are available and this entry does not choose between them:
- Oversight. The conditioning chapter was written by the transplant advisor (the protocol names Christina Peters) and inherits transplant conventions, in which the reference patient is an older child; the frontline chapters were written by infant leukaemia investigators for whom age adjustment is routine.
- Deliberate. Conditioning is intended to be myeloablative and a dose reduction would risk graft failure or relapse - the tolerance for underdosing is lower than in maintenance chemotherapy, so the calculation genuinely differs.
The second is defensible. It is also exactly the reasoning that would be settled by measuring exposure rather than by argument, and Interfant-06 made that measurement optional.
| protocol position | Interfant-06 applies age-based dose reductions in its chemotherapy chapters (cyclophosphamide x2/3 under 6 months, x3/4 from 6-12 months) and NO age adjustment anywhere in its conditioning chapter; the conditioning chapter has a different named author |
|---|---|
| which reading would be settled by | measuring exposure rather than arguing about units - which Interfant-06 made optional |
maturing systems and agents
{
"glomerular_filtration": "rises steeply from birth towards adult values over 1-2 years; governs fludarabine (F-ara-A is renally cleared) and partly melphalan",
"cyp450_ontogeny": "CYP2B6 and CYP3A4 low at birth, rising on developmentally staged schedules; activate thiotepa to TEPA and cyclophosphamide to phosphoramide mustard",
"glutathione_conjugation": "GSTA1-mediated; clears busulfan",
"body_composition": "total body water per kilogram highest in infancy, altering volume of distribution of hydrophilic agents"
}measured consequences
{
"fludarabine": "PBPK exposure prediction better from nuclear GFR than estimated GFR; eGFR depends on creatinine, which depends on muscle mass, which an infant has least of",
"busulfan": "at identical exposure, mixed donor myeloid chimerism 45.2% under 3 years versus 1.9% at 3 years or older - a pharmacodynamic age effect that dosing cannot correct",
"thiotepa": "clearance and half-life comparable between paediatric and adult patients in one phase 1 study; only BSA-normalised volume of distribution differed as expected - ontogeny is a reason to check, not to assume"
}two readings of that
[ "Oversight: transplant conventions were imported wholesale from a population whose reference patient is an older child", "Deliberate: conditioning must be myeloablative and the penalty for underdosing (graft failure, relapse) is immediately lethal, unlike an underdosed maintenance course" ]
- Some age effects cannot be dosed away. The clearest infant-versus-older-child difference found by this beat - 45.2% versus 1.9% mixed chimerism - occurred at identical drug exposure, so perfecting pharmacokinetics would not have closed it.
- The covariate that governs the dose is measured worst in the patient who needs it most. Estimated GFR depends on creatinine, creatinine depends on muscle, and an infant has almost none - so the standard renal adjustment is close to uninformative exactly where renal function is changing fastest.
- Four systems are maturing at once and they do not mature together. Renal clearance, CYP ontogeny, conjugation capacity and body water follow different schedules, so there is no single developmental correction factor and no age at which all four are 'adult enough'.
- Treating the first year as one category means a two-month-old and an eleven-month-old receive the same mg/kg dose of three alkylators, and the protocol's own chemotherapy chapters concede that this is wrong by adjusting at exactly the six-month boundary it ignores in conditioning.
- Ontogeny is a reason to check and not a reason to assume. Thiotepa's clearance turned out to be comparable between children and adults; asserting an infant difference without measuring it produces confident wrong dosing in the opposite direction.
- Does the under-3-years chimerism effect hold below 12 months, and does it hold in leukaemia? The published cut-point is 3 years in non-malignant disease, and in leukaemia mixed chimerism means residual host haematopoiesis that may include residual disease.
- Which conditioning agents actually behave differently in infants? Thiotepa's clearance was comparable to adults; busulfan's and fludarabine's are not established below 12 months. The list of agents where ontogeny matters has never been assembled empirically for this regimen.
- Would a measured GFR before conditioning change infant fludarabine dosing enough to matter? Nuclear GFR improved model prediction but is not routinely available, and the clinical benefit of that improvement has not been isolated.
- Is the absence of age adjustment in Interfant-06 conditioning deliberate or inherited? The conditioning chapter has a different named author from the chemotherapy chapters, and the answer determines whether this is a correctable gap or a considered position.
- E1established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.review
Drug disposition, action and therapy in infants and children are governed by developmentally changing physiological processes rather than by body size alone, which is the standing framework for paediatric pharmacology.
Developmental pharmacology--drug disposition, action, and therapy in infants and children. · Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE · The New England Journal of Medicine 2003What this evidence cannot show
A 2003 narrative review, cited as the standing framework and not as evidence for any specific number in this entry. PubMed returns no abstract for this record, so the citation rests on the title and on the article's status as the field's reference review; the specific ontogeny schedules attributed to individual enzymes in this entry's table are general pharmacological knowledge and are NOT quoted from this paper. It contains nothing about transplant conditioning or about any of the agents discussed here.
Evidence that argues against this (1)
- A general framework does not establish that any particular conditioning agent behaves differently in infants. Where the question has actually been asked for an agent in this regimen, the answer has sometimes been that it does not: thiotepa clearance and biological half-life were comparable between paediatric and adult patients in a phase 1 study, with only the surface-area-normalised volume of distribution differing as expected. Ontogeny is a reason to check, not a reason to assume. Kondo E et al. 2019
- E2moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
In a physiologically based pharmacokinetic virtual-twin analysis of 28 paediatric HSCT patients, informing the fludarabine model with plasma protein scaling factor and NUCLEAR glomerular filtration rate improved prediction of individual drug exposure (mean fold error 0.91 total, 0.88 unbound) over the model informed by estimated GFR.
Physiologically Based Pharmacokinetic Virtual Twin Approach for Fludarabine Dosing in Pediatric Hematopoietic Stem Cell Transplantation. · Mseddi M, Nath C, Ben Hassine K, Mlakar V, Gloor Y, Gonzales F, Uppugunduri CRS, Daali Y, et al. · CPT: Pharmacometrics & Systems Pharmacology 2026What this evidence cannot show
Twenty-eight patients, no clinical outcome endpoint, and a model built 'middle-out' from literature data so that its structural assumptions are inherited rather than fitted. The age distribution of the 28 patients is not given in the abstract and infants are not separately reported. The argument in this entry that the eGFR problem is worst in infancy, because creatinine derives from muscle mass, is this beat's physiological reasoning and is NOT a finding of the paper. Nuclear GFR is not routinely measured before transplant.
Evidence that argues against this (1)
- Improved exposure prediction is not improved outcome, and nuclear GFR measurement is not available in most centres before conditioning. The clinical comparison that does exist tested model-based against body-surface-area fludarabine dosing without requiring nuclear GFR, and found a benefit concentrated in patients who already carried other rejection risk factors - so the practical gain from better renal covariates specifically is unquantified. Dvorak CC et al. 2026
- E3moderate confidence 3 of 5: One strong study, or several smaller consistent ones.paper
In 105 children with non-malignant disease receiving myeloablative busulfan-based conditioning, the 3-year cumulative incidence of mixed donor myeloid chimerism was 45.2% (95% CI 29.7-60.7) below 3 years of age versus 1.9% (0.1-5.4) at 3 years or older (p<0.001), with no difference in busulfan exposure between the age groups; minimal donor chimerism was 12.8% versus 0% (p=0.008).
Younger children with nonmalignant disease have increased incidence of mixed myeloid chimerism after allogeneic hematopoietic cell transplantation with busulfan-based conditioning. · Dvorak CC, Temple WC, Cisneros GS, Chu J, Winestone LE, Higham CS, Shimano KA, Kharbanda S, et al. · Transplantation and Cellular Therapy 2025What this evidence cannot show
Non-malignant disease only, retrospective, single institution, 105 patients over 16 years, with the 2.9-year cut-off derived by ROC analysis in the same dataset rather than prespecified. The proposed mechanism - greater marrow reserve in younger children - is a hypothesis and was not measured. Mixed chimerism carries entirely different clinical meaning in leukaemia (relapse risk) than in a genetic disease (partial correction), so the finding does not transfer directly. Whether the effect operates below 1 year specifically is not reported; the comparison is above and below 3 years.
Evidence that argues against this (1)
- The same study found NO impact of age or busulfan exposure on immunologic graft rejection, acute or chronic GVHD, transplant-related mortality or sinusoidal obstruction syndrome. The age effect is confined to the degree of myeloid replacement and does not propagate to any clinical endpoint measured, so reading it as 'conditioning works less well in young children' overstates what was found. Dvorak CC et al. 2025
- E4established confidence 5 of 5: Multiple independent lines of evidence; treated as settled in the field.book
The Interfant-06 conditioning chapter specifies fixed doses (busulfan 5 mg/kg/day, cyclophosphamide 60 mg/kg, melphalan 140 mg/m2, ATG 20 mg/kg) with no age-based adjustment, its only stated size rule being for very obese children; the same protocol's chemotherapy chapters apply age-based dose reductions.
INTERFANT-06: International collaborative treatment protocol for infants under one year with acute lymphoblastic or biphenotypic leukemia (protocol document, SKION version 01, April 2006) · Pieters R, de Lorenzo P, Valsecchi MG, Peters C, and the Interfant-06 study group · Interfant-06 study group / SKION protocol document 2006What this evidence cannot show
Chapter 6 of the 2006 SKION document, read on 2026-09-20. The statement that the conditioning chapter contains no age adjustment is an absence in a document read in full, which is a stronger form of absence than a database query, but it is bounded to this version of this protocol - later amendments were not retrieved. Section 1.3.5 states that donor selection, conditioning and GVHD prophylaxis were 'performed as advised by Christina Peters', so the conditioning chapter has a different author from the chemotherapy chapters, which may explain the difference in convention.
Evidence that argues against this (1)
- The absence of an age adjustment in conditioning may be deliberate rather than an oversight. Conditioning is intended to be myeloablative and the tolerance for underdosing is far lower than in maintenance chemotherapy: an underdosed conditioning regimen risks graft failure or relapse, both of which are immediately lethal, whereas an underdosed maintenance course is recoverable. The FORUM exposure data support that asymmetry directly, with underexposure carrying a relapse hazard ratio of 1.93. Ben Hassine K et al. 2026
which size unit is right depends on which maturing organ system clears the agent
CYP2B6/CYP3A4 desulfuration to TEPA is developmentally staged; thiotepa clearance itself was comparable between children and adults in one phase 1 study
CYP2B6/CYP3A4 4-hydroxylation is required for activation and is developmentally staged
- part of →Interfant-06 — 651 infants, and the definitive answer that myeloid-style consolidation does not help
the conditioning chapter has a different named author from the chemotherapy chapters and carries no age adjustment
four organ systems maturing at once in the population the whole protocol treats as one age category
three alkylators in eight days through a maturing hepatic conjugating system
a pharmacodynamic age effect at identical exposure - the one age difference dosing cannot correct
F-ara-A is renally cleared and glomerular filtration is maturing through the first two years